Abstract: The present disclosure provides compositions comprising novel mass tags. The disclosure also provides methods utilizing mass tags, including methods of quantifying one or more individual lipids from a composition of lipids, methods of identifying a double bond position of an individual lipid, methods of identifying a biological correlation of an individual lipid, and methods of preparing a lipid derivative.

Abstract: The present invention is directed to certain 2-aminoquinzaoline derivatives of Formula (I): and pharmaceutically acceptable salts thereof, wherein R1, R3, R4, X1, and X2 are as defined herein, which are potent inhibitors of LRRK2 kinase and may be useful in the treatment or prevention of diseases in which the LRRK2 kinase is involved, such as Parkinson's Disease and other diseases and disorders described herein. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which LRRK-2 kinase is involved.

Abstract: The present invention is directed to substituted certain N-(heteroaryl)quinazolin-2-amine derivatives of Formula (I): and pharmaceutically acceptable salts thereof, wherein J, R3, and R4, are as defined herein, which are potent inhibitors of LRRK2 kinase and may be useful in the treatment or prevention of diseases in which the LRRK2 kinase is involved, such as Parkinson's Disease and other diseases and disorders described herein. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of diseases, such as Parkinson's disease, in which LRRK-2 kinase is involved.

Abstract: The present disclosure relates to compounds of Formula (I): and to their prodrugs, pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful for modulating DNA polymerase ? activity and may be used in the treatment of disorders in which DNA polymerase ? activity is implicated, such as cancer.

Abstract: The present invention is directed to certain 2-aminoquinzaoline derivatives of Formula (I) and pharmaceutically acceptable salts thereof, wherein R1, R2, and R3 are as defined herein, which are potent inhibitors of LRRK2 kinase and may be useful in the treatment or prevention of diseases in which the LRRK2 kinase is involved, such as Parkinson's Disease and other diseases and disorders described herein. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which LRRK-2 kinase is involved.

Abstract: The present disclosure relates to compounds of Formula (I?): and to their prodrugs, pharmaceutically acceptable salts, pharmaceutical compositions, methods of use, and methods for their preparation. The compounds disclosed herein are useful for modulating Werner Helicase (WRN) activity and may be used in the treatment of disorders in which WRN activity is implicated, such as cancer.

Abstract: The invention generally relates to systems and methods for on-line reaction monitoring. In certain embodiments, the invention provides systems that include a reaction vessel having an outlet, a quantitation unit coupled to the outlet and configured to introduce internal standard and solvent into reaction solution flowed from the reaction vessel, one or more ion generating devices that receive flow from the quantitation unit, and a mass spectrometer. In certain embodiments, the invention provides systems for multiple reaction monitoring that include a plurality of reaction vessels, a plurality of ion generating devices, a plurality of channels, each channel coupling a reaction vessel to an ion generating device, an actuator coupled to the plurality of ion generating devices to thereby allow movement of the plurality of ion generating devices, and a mass spectrometer.

Abstract: The present disclosure provides compositions, kits, and methods for identifying one or more lipid isomers in a sample.

Abstract: Described herein are compounds of Formula I or a pharmaceutically acceptable salt thereof. The compounds of Formula I act as IL4I1 inhibitors and can be useful in preventing, treating or acting as a remedial agent for IL4I1-related diseases.

Abstract: Methods for identifying a structural feature of a lipid include: (a) conducting at least one voltage-controlled electrochemical reaction that converts the lipid to a first derivatized lipid; and (b) fragmenting the first derivatized lipid to generate at least one diagnostic ion indicative of a first structural feature of the lipid.

Abstract: The present invention is directed to certain 2-aminoquinzaoline derivatives of Formula (I) and (Ia); and pharmaceutically acceptable salts thereof, which are potent inhibitors of LRRK2 kinase and may be useful in the treatment or prevention of diseases in which the LRRK2 kinase is involved, such as Parkinson's Disease and other diseases and disorders described herein. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which LRRK-2 kinase is involved.

Abstract: A battery and an electric device are described. The battery includes a plurality of battery cells, the plurality of battery cells are arranged in a matrix along a first direction and a second direction, the first direction being perpendicular to the second direction; and an insulating member, including a first insulating portion extending along the first direction and a second insulating portion extending along the second direction, the first insulating portion is fixedly connected to the plurality of battery cells arranged along the first direction, and the second insulating portion is fixedly connected to the plurality of battery cells arranged along the second direction.

Abstract: Embodiments of this application provide a storage component, a preparation method, a reading/writing method, a storage chip, and an electronic device, is related to the storage technology field, and is used to resolve a problem that a quantity of storage states of a spin orbit torque-magnetic random access memory is increased while a storage state change range remains unchanged. The storage component includes: a first magnetic tunnel junction, a spin orbit coupling layer and a second magnetic tunnel junction that are sequentially arranged in a stacked manner. The first magnetic tunnel junction includes a first free layer, and the second magnetic tunnel junction includes a second free layer. The first free layer and the second free layer are arranged on two opposite surfaces of the spin orbit coupling layer.

Abstract: Techniques are described herein that are capable of converting pages written in page storage during a user session to page-embedded blocks in block storage for reading. Blocks of first data are read from block storage during a user session. Pages of second data are written to page storage during the user session. The pages of the second data indicate changes to be made with regard to at least a subset of the blocks of the first data in the block storage. At a time instance at which no pages are being written to the page storage, the pages of the second data are transferred from the page storage to the block storage by converting the pages of the second data, which are configured to have a page format associated with the page storage, to page-embedded blocks, which are configured to have a block format associated with the block storage.

Abstract: The invention generally relates to methods and devices for synchronization of ion generation with cycling of a discontinuous atmospheric interface. In certain embodiments, the invention provides a system for analyzing a sample that includes a mass spectrometry probe that generates sample ions, a discontinuous atmospheric interface, and a mass analyzer, in which the system is configured such that ion formation is synchronized with cycling of the discontinuous atmospheric interface.

Abstract: The present invention is directed to substituted certain 1-pyrazolyl, 5-, 6-disubstituted indazole derivatives of Formula (I) and pharmaceutically acceptable salts thereof, wherein R1, R2, and ring A are as defined herein, which are potent inhibitors of LRRK2 kinase and may be useful in the treatment or prevention of diseases in which the LRRK2 kinase is involved, such as Parkinson's Disease and other diseases and disorders described herein. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of diseases, such as Parkinson's disease, in which LRRK-2 kinase is involved.

Abstract: Provided are a communication network switching apparatus, a communication network switching system, and a communication network switching method. The apparatus includes a first communication network interface, a second communication network interface, a processor, a communication network switch, and a device access interface. The communication network switch is configured to switch, according to the control signal of the processor, the connection manner with the first communication network interface and the second communication network interface and connect the first communication network or the second communication network to the processor. The processor is connected to the device access interface and is configured to connect a target communication network connected through the communication network switch to a target device connected to the device access interface.

Abstract: Disclosed is a long-distance punching method and device for power generation enterprises, including the following steps: determining the employee geographical position of a target employee according to an employee identification code; calculating the distance value between employee geographical position and enterprise geographical position, and generating a long-distance punching strategy according to the distance value, demand punching time and demand punching method; calculating the time interval of employee punching time according to the timestamp, and generating the employee punching strategy; extracting a first core punching semantics in the long-distance punching strategy, extracting a second core punching semantics in the employee punching strategy, and calculating a matching value between the first core punching semantics and the second core punching semantics; and performing a feedback and updating of the employee punching strategy to obtain an updated employee punching strategy, and performing a lon

Abstract: A device suspension method and a computing device are provided. In the method, before a device enters a suspended state, memory space occupied by a background process that is unrelated to a foreground process is released. In this way, the background process unrelated to the foreground process is not saved in a memory of the device. In other words, it reduces data stored in the memory when the device is suspended. Therefore, when the device needs to be woken up, only a relatively small amount of data needs to be read from the memory, and a working state can be rapidly restored. This can reduce a delay of reading data from the memory when the device is woken up, thereby accelerating a wakeup speed of the device. In addition, the data is stored in the memory when the device is suspended.

Abstract: The present invention is directed to certain 2-aminoquinzaoline derivatives of Formula (I): Formula (I) and pharmaceutically acceptable salts thereof, wherein R1, R2, and R3 are as defined herein, which are potent inhibitors of LRRK2 kinase and may be useful in the treatment or prevention of diseases in which the LRRK2 kinase is involved, such as Parkinson's Disease and other diseases and disorders described herein. The invention is also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the prevention or treatment of such diseases in which LRRK-2 kinase is involved.